Rhythm Pharmaceuticals Inc (RYTM) CEO Keith Michael Gottesdiener Sells 10,115 Shares

Share on StockTwits

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) CEO Keith Michael Gottesdiener sold 10,115 shares of the firm’s stock in a transaction on Friday, January 18th. The shares were sold at an average price of $30.01, for a total value of $303,551.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Keith Michael Gottesdiener also recently made the following trade(s):

  • On Wednesday, February 13th, Keith Michael Gottesdiener sold 3,934 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $118,020.00.
  • On Wednesday, January 23rd, Keith Michael Gottesdiener sold 15,779 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.05, for a total value of $474,158.95.
  • On Wednesday, January 16th, Keith Michael Gottesdiener sold 662 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $19,860.00.
  • On Friday, November 2nd, Keith Michael Gottesdiener sold 16,500 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.08, for a total value of $496,320.00.

Shares of NASDAQ:RYTM traded up $0.33 during trading on Friday, hitting $30.04. 85,269 shares of the company’s stock traded hands, compared to its average volume of 87,562. Rhythm Pharmaceuticals Inc has a 52 week low of $16.80 and a 52 week high of $37.23. The stock has a market capitalization of $1.03 billion, a PE ratio of -10.61 and a beta of 1.41.

Several large investors have recently added to or reduced their stakes in RYTM. Bank of New York Mellon Corp lifted its holdings in shares of Rhythm Pharmaceuticals by 55.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,793 shares of the company’s stock valued at $1,181,000 after purchasing an additional 13,462 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Rhythm Pharmaceuticals by 49.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 47,595 shares of the company’s stock valued at $1,488,000 after purchasing an additional 15,695 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Rhythm Pharmaceuticals by 93.8% during the 2nd quarter. BlackRock Inc. now owns 747,669 shares of the company’s stock valued at $23,371,000 after purchasing an additional 361,867 shares in the last quarter. FMR LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 40.9% during the 2nd quarter. FMR LLC now owns 1,825,634 shares of the company’s stock valued at $57,069,000 after purchasing an additional 529,834 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Rhythm Pharmaceuticals by 110.5% during the 2nd quarter. Bank of America Corp DE now owns 6,251 shares of the company’s stock valued at $195,000 after purchasing an additional 3,282 shares in the last quarter. Institutional investors and hedge funds own 90.56% of the company’s stock.

A number of brokerages have issued reports on RYTM. Zacks Investment Research cut Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 15th. Stifel Nicolaus restated a “hold” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 13th. BidaskClub upgraded Rhythm Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 10th. Finally, Needham & Company LLC set a $42.00 target price on Rhythm Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $38.25.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Highlight Press and is owned by of Highlight Press. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://highlightpress.com/2019/02/16/rhythm-pharmaceuticals-inc-rytm-ceo-sells-303551-15-in-stock.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.

Featured Story: Hedge Funds Explained

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply